News


( Last Updated : March 7, 2015)

February 4, 2022
OTTAWA, February 4, 2022 ─ CADTH is pleased to announce it is expanding its expertise in the management of pharmaceuticals in Canada with the creation of a new Post-Market Drug Evaluation (PMDE) Program. The PMDE Program will be responsible for launching and coordinating a network that leverages…
January 28, 2022
Human papillomavirus (HPV) is a common infection of the reproductive tract. Approximately 97% of cervical cancer cases are attributed to 12 strains of HPV, and 2 specific strains cause 70% of cervical cancer cases. Each year, around 1,300 women across Canada will be diagnosed with cervical cancer…
January 11, 2022
In July 2021, CADTH convened an advisory panel to provide Health Canada with a recommended framework for developing a potential pan-Canadian prescription drug list or formulary.  On January 18, 2022, the advisory panel and CADTH will host an information session on the panel’s work so far. In…
December 10, 2021
CADTH is pleased to let you know that the abstracts for the 2021 CADTH Symposium have been published in a special supplement to Volume 1, Number 12 of the Canadian Journal of Health Technologies ― CADTH’s official open-access scientific and policy journal. These abstracts include poster, oral,…
December 6, 2021
With growing concern globally about the impact of post–COVID-19 condition (also known as “long COVID”) and its emergence as a new chronic condition, scientists and clinicians from around the world are working together to help us better understand it. In anticipation of the evolving needs of…